Archean Chemical Industries (ACI) Q4 22/23 earnings summary

Executive summary

• FY23 standalone revenue rose 27.5% YoY to ₹1,44,106.59 lakh; PAT more than doubled to ₹38,365.38 lakh, supported by stronger product mix and price realization.

• Bromine and industrial salt drove performance; IPO proceeds funded debt repayment, while the bromine capacity expansion is intended to support downstream derivatives.

Financial highlights

• Standalone revenue from operations was ₹1,44,106.59 lakh vs ₹1,13,043.71 lakh in FY22; EBITDA was ₹67,854.65 lakh vs ₹47,994.80 lakh.

• Standalone PAT rose to ₹38,365.38 lakh from ₹18,861.39 lakh; basic EPS increased to ₹34.76 from ₹18.26.

• Consolidated revenue was ₹1,44,106.59 lakh and PAT ₹38,255.92 lakh; consolidated basic EPS was ₹34.66 vs ₹18.22.

• Other income included a ₹1,569.11 lakh insurance claim; total other income was ₹4,417.89 lakh vs ₹1,264.29 lakh in FY22.

Outlook and guidance

• Bromine capacity expanded by 14,500 tonnes/year to 43,000 tonnes in FY23; incremental capacity is intended for captive use in downstream derivatives.

• Technical issues in potash raw-material preparation were addressed; production was expected to improve in coming years.

• Indian specialty chemicals demand was expected to grow on exports and domestic demand, with China’s environmental changes and China+1 sourcing creating potential opportunities.